Total Polyunsaturated Fatty Acid Level in Abdominal Adipose Tissue as an Independent Predictor of Recurrence-Free Survival in Women with Ovarian Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Jan 2023
Historique:
received: 03 11 2022
revised: 01 01 2023
accepted: 05 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Prognostic factors for epithelial ovarian cancers (EOCs) are in particular clinical factors such as pathology staging at diagnosis (FIGO stages), genetic mutation, or histological phenotypes. In the present study, FIGO stage, tumor residue after surgery, and body mass index were clinical predictors of recurrence-free survival (RFS). Nonetheless, a number of studies support a lipid metabolism disorder in ovarian cancer patients. The objective of this pilot study was to explore whether fatty acid composition of adipose reflecting the qualitative dietary intake and fatty acids metabolism may be associated with RFS. Forty-six women with EOCs and six with borderline ovarian tumors between March 2017 and January 2020 were included in this prospective study at Tours university teaching hospital (central France). The patients involved in the present study are part of the METERMUS trial (clinicaltrials.gov NCT03027479). Adipose tissue specimens from four abdominal locations (superficial and deep subcutaneous, visceral (pericolic), and omental) were collected during surgery or exploratory laparoscopy. A fatty acid profile of adipose tissue triglycerides was established by gas chromatography. Fatty acids composition was compared among the four locations using nonparametric Friedman’s ANOVA test for repeated measures. Median follow-up of EOC patients was 15 months and patients’ RFS was analyzed using Kaplan−Meier survival curves and log-rank test by separating patients into two groups according to median fatty acid levels. The content of long-chain saturated fatty acids (SFAs) was increased and that of long-chain polyunsaturated fatty acids (PUFAs) decreased in deep versus superficial subcutaneous adipose tissue in EOC patients. Nevertheless, the content of total SFAs was ~28%, monounsaturated fatty acids (MUFAs) ~55%, PUFAs n-6 ~11.5%, and PUFAs n-3 about 1.3%, whatever the adipose tissue. When EOC patients were separated into two groups by median fatty acid content, total PUFAs (n-6+n-3) levels, whatever the adipose tissue, were positively and independently associated with RFS. RFS was about two times longer in EOC patients with high versus low total PUFA content (median survival: 12 vs. 27 months, p = 0.01 to <0.0001 according to the tissue). Content of total PUFAs (n-6+n-3) in abdominal adipose tissue (visceral and subcutaneous) are new prognostic factors in EOC.

Identifiants

pubmed: 36675280
pii: ijms24021768
doi: 10.3390/ijms24021768
pmc: PMC9863501
pii:
doi:

Substances chimiques

Fatty Acids, Unsaturated 0
Fatty Acids 0

Banques de données

ClinicalTrials.gov
['NCT03027479']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : INSERM
ID : NA
Organisme : UNIVERSITE DE TOURS
ID : NA
Organisme : CANCEROPOLE GRAND OUEST
ID : NA
Organisme : LA LIGUE CONTRE LE CANCER
ID : NA
Organisme : REGION CENTRE VAL DE LOIRE
ID : NA

Références

Biochem J. 1997 Jun 15;324 ( Pt 3):911-5
pubmed: 9210416
Nutr Cancer. 2016 Jul;68(5):772-9
pubmed: 27044606
Ecancermedicalscience. 2016 Mar 08;10:626
pubmed: 27110282
J Natl Cancer Inst. 2014 Oct 21;106(11):
pubmed: 25335480
Int J Gynecol Cancer. 2017 May;27(4):668-674
pubmed: 28441250
Int J Obes (Lond). 2006 Jun;30(6):899-905
pubmed: 16446749
Nat Commun. 2018 Jul 26;9(1):2923
pubmed: 30050129
Front Cell Dev Biol. 2020 Sep 22;8:571648
pubmed: 33072753
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14
pubmed: 27743768
Cancer Lett. 2017 Aug 10;401:39-45
pubmed: 28527945
Biomedicines. 2022 Apr 26;10(5):
pubmed: 35625732
Acta Obstet Gynecol Scand. 2010;89(1):101-7
pubmed: 19878086
Obesity (Silver Spring). 2010 May;18(5):937-44
pubmed: 19798063
Sci Rep. 2020 Feb 6;10(1):1954
pubmed: 32029824
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):534-546
pubmed: 31999069
Cell Physiol Biochem. 2017;41(2):722-730
pubmed: 28214830
Sci Rep. 2019 Aug 5;9(1):11333
pubmed: 31383894
Cancer Causes Control. 2008 Nov;19(9):909-16
pubmed: 18392944
Br J Cancer. 2017 Jun 6;116(12):1627-1637
pubmed: 28463959
Post Reprod Health. 2017 Dec;23(4):183-198
pubmed: 28720017
Gynecol Oncol. 1996 Jan;60(1):35-41
pubmed: 8557225
Nutr Rev. 2016 Dec;74(12):737-748
pubmed: 27864535
Prog Lipid Res. 2008 Sep;47(5):348-80
pubmed: 18435934
PLoS One. 2015 Oct 12;10(10):e0140403
pubmed: 26457674
Cell Rep. 2019 Dec 10;29(11):3726-3735.e4
pubmed: 31825847
Ann Oncol. 2009 May;20 Suppl 4:21-3
pubmed: 19454452
Cancer Lett. 1997 Jan 1;111(1-2):179-85
pubmed: 9022144
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Am J Clin Nutr. 2000 Jun;71(6):1470-7
pubmed: 10837287
Int J Mol Sci. 2022 Feb 16;23(4):
pubmed: 35216285
Clin Cancer Res. 2017 Apr 15;23(8):2081-2092
pubmed: 27797973
JAMA Netw Open. 2019 Mar 1;2(3):e190429
pubmed: 30848812
Cancer. 2006 Oct 1;107(7):1520-4
pubmed: 16941453
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Obes Rev. 2010 Jan;11(1):11-8
pubmed: 19656312
PLoS One. 2016 Jan 26;11(1):e0147148
pubmed: 26812254
Int Sch Res Notices. 2014 Oct 29;2014:953509
pubmed: 27382614
Int J Gynaecol Obstet. 2018 Nov;143(2):232-238
pubmed: 30112762
J Obstet Gynaecol Res. 2012 Jan;38(1):70-6
pubmed: 21827578
Nat Commun. 2017 May 23;8:15253
pubmed: 28534500
Front Oncol. 2020 Oct 19;10:593017
pubmed: 33194756
Eur J Clin Nutr. 1997 Sep;51(9):619-24
pubmed: 9306089
Diagnostics (Basel). 2017 Mar 02;7(1):
pubmed: 28257098
Am J Physiol Endocrinol Metab. 2004 Apr;286(4):E577-88
pubmed: 14600072
Am J Clin Nutr. 2001 Nov;74(5):585-91
pubmed: 11684525
Genes Nutr. 2014 Jul;9(4):409
pubmed: 24895107
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Nutr Soc. 2016 May;75(2):188-98
pubmed: 26743210
Support Care Cancer. 2010 Mar;18(3):373-81
pubmed: 19484479
Nature. 2011 Sep 25;478(7367):110-3
pubmed: 21947005
Virchows Arch. 2012 Mar;460(3):237-49
pubmed: 22322322
Ann Oncol. 2008 May;19(5):898-902
pubmed: 18272913

Auteurs

Helene Salaun (H)

Department of Oncology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.
Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.

Mathilde Poisson (M)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.

Adeline Dolly (A)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.

Flavie Arbion (F)

Department of Pathology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.

Stéphane Servais (S)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.

Jean François Dumas (JF)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.

Caroline Goupille (C)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.
Department of Gynecology, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.

Lobna Ouldamer (L)

Laboratoire «Nutrition, Croissance et Cancer», INSERM UMR1069, Université de Tours, 10 Boulevard Tonnellé, 37044 Tours, France.
Department of Gynecology, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH